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ABSTRACT
Poxviruses, such as vaccinia virus (VACV), undertake a complex cytoplasmic replication cycle which involves morphogenesis
through four distinct virion forms and includes a crucial wrapping step whereby intracellular mature virions (IMVs) are
wrapped in two additional membranes to form intracellular enveloped virions (IEVs). To determine if cellular retrograde trans-
port pathways are required for this wrapping step, we examined VACVmorphogenesis in cells with reduced expression of the
tetrameric tethering factor known as the GARP (Golgi-associated retrograde pathway), a central component of retrograde trans-
port. VACVmultistep replication was significantly impaired in cells transfected with small interfering RNA targeting the GARP
complex and in cells with a mutated GARP complex. Detailed analysis revealed that depletion of the GARP complex resulted in a
reduction in the number of IEVs, thereby linking retrograde transport with the wrapping of IMVs. In addition, foci of viral
wrapping membrane proteins without an associated internal core accumulated in cells with a mutated GARP complex, suggest-
ing that impaired retrograde transport uncouples nascent IMVs from the IEVmembranes at the site of wrapping. Finally, small-
molecule inhibitors of retrograde transport strongly suppressed VACVmultistep growth in vitro and reduced weight loss and
clinical signs in an in vivomurine model of systemic poxviral disease. This work links cellular retrograde transport pathways
with the morphogenesis of poxviruses and identifies a panel of novel inhibitors of poxvirus replication.
IMPORTANCE
Cellular retrograde transport pathways traffic cargo from endosomes to the trans-Golgi network and are a key part of the intra-
cellular membrane network. This work reveals that the prototypic poxvirus vaccinia virus (VACV) exploits cellular retrograde
transport pathways to facilitate the wrapping of intracellular mature virions and therefore promote the production of extracellu-
lar virus. Inhibition of retrograde transport by small-molecule inhibitors reduced the replication of VACV in cell culture and
alleviated disease in mice experimentally infected with VACV. This research provides fundamental new knowledge about the
wrapping step of poxvirus morphogenesis, furthers our knowledge of the complex cellular retrograde pathways, and identifies a
new group of antipoxvirus drugs.
Vaccinia virus (VACV) is the prototypic orthopoxvirus. It is alarge double-stranded DNA virus with a complicated intracy-
toplasmic life cycle involving progression through four virion
forms. The initial and most abundant virion type is the intracel-
lular mature virion (IMV), which consists of a viral core sur-
rounded by a single membrane. IMVs are fully infectious and can
be released on cell lysis. Prior to lysis, a minority of the IMVs are
wrapped in a double membrane to form intracellular enveloped
virions (IEV), which have three membranes (reviewed in refer-
ence 1). The origin of both the IMV and IEV membranes is much
debated (2). Once it is wrapped, the IEV is transported to the cell
periphery, where its outer membrane fuses with the plasma mem-
brane to form a double-wrapped cell-associated enveloped virion
(CEV) on the surface of the cell. A selection of IEV-associated viral
proteins becomes embedded in the plasma membrane of the cell
as a result of this membrane fusion event. A proportion of the
CEVs stimulates actin polymerization, resulting in the formation
of actin tails (3, 4). Once CEVs detach from the cell surface, they
are known as extracellular enveloped virions (EEVs) (1). CEVs
and EEVs are few in number (often only 1% of the number of
IMVs present in the cell) but crucial for the virus since they me-
diate spread between neighboring cells and to more distant cells in
vitro and in vivo (5–7).
Previous research has suggested that VACV may use retrograde
transport pathways as part of its complex virion morphogenesis.
The viral IEV membrane proteins A33, A36, B5, and F13 were
found to accumulate at the plasma membrane following disrup-
tion of clathrin-mediated endocytosis (8–10), leading to the hy-
pothesis that clathrin-mediated endocytosis is the first step in ret-
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rograde transport of these proteins. In addition, two independent
studies reported the very rapid transport of horseradish peroxi-
dase (HRP) from the cell surface to the Golgi apparatus in VACV-
infected cells (11, 12), indicating that the virus stimulates retro-
grade transport. More recently, endosome-to-Golgi retrograde
transport pathway (EGRTP) proteins have been identified to be
proviral host factors in two independent high-throughput small
interfering RNA (siRNA) screens of VACV replication (13, 14).
This evidence collectively supports the utilization of EGRTP by
VACV; however, direct evidence is lacking.
EGRTPs are used by the cell to recycle cargo back to the trans-
Golgi network (TGN) for reuse. The pathway can begin at early,
late, or recycling endosomes, where cargo-sorting complexes,
such as retromer, recognize and select cargo and sort it into vesi-
cles, which are then transported to the TGN (15). Tethering fac-
tors, such as golgin-97 and the GARP (Golgi-associated retro-
grade protein) complex, tether the transport intermediates to the
TGN and enable SNARE (soluble N-ethylmaleimide-sensitive fu-
sion factor attachment receptor) complexes on the transport ves-
icles (vSNAREs) and target membrane (tSNAREs) to promote
membrane fusion. Tethers are targeted to the TGN by small
GTPases of the Rab family. Different cargoes use different combi-
nations of cargo sorters, SNAREs, tethers, and GTPases (16).
Well-characterized endogenous cargoes that are transported
along retrograde pathways include mannose 6-phosphate recep-
tor, TGN-46 (17), sphingolipids (18), and 1 integrin (19). In
addition to cellular proteins, toxins also transit along retrograde
vesicle pathways to access their site of action, including Shiga
toxin, Shiga-like toxins 1 and 2, ricin, and cholera toxin (16). A
number of viruses also utilize the pathway; for example, HIV uses
it for trafficking of envelope glycoprotein (Env) (20), human pap-
illomavirus 16 (HPV16) uses it for entry (21), and adeno-associ-
ated virus (AAV) uses it for transduction (22). Endosome-to-
Golgi retrograde pathways are therefore key physiological
transport routes that are also implicated in a number of patho-
genic mechanisms.
This work outlines the role of EGRTP in VACV replication.
The tetrameric tethering factor GARP was shown to be required
for the progression of IMVs to EEVs and, more specifically, for the
wrapping of IMVs to produce IEVs. A reduction in the amount of
GARP markedly reduced the number of IEVs in the cell and
caused cytoplasmic accumulation of aberrant structures contain-
ing IEV membrane proteins. The retrograde pathway used by
VACV was found to be independent of retromer but was inhibited
by small-molecule inhibitors of the EGRTP, including Retro-2.
Further, intraperitoneal (i.p.) treatment of mice with Retro-2
prior to intranasal infection with VACV ameliorated weight loss
and significantly reduced signs of disease, identifying EGRTP as a
therapeutic target for preventing poxviral infection.
MATERIALS AND METHODS
Cells and viruses. Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies) containing 50g/ml streptomycin and 50g/ml penicillin
(pen/strep; Sigma) with 10% fetal bovine serum (FBS; Life Technologies)
was used to grow the following cell lines: rabbit kidney epithelial (RK-13)
cells, African green monkey kidney epithelial (BS-C-1 and Vero) cells, and
human cervix carcinoma epithelial (HeLa) cells. All cell lines were pas-
saged regularly to maintain viability. Cells were washed in phosphate-
buffered saline (PBS) and detached using 0.5% trypsin–EDTA (Life Tech-
nologies) before transfer to a fresh tissue culture flask. Wild-type (WT)
and mutant (MU) mouse embryonic fibroblasts (MEFs) were provided by
one of the authors (Thomas Schmitt-John) and were grown in pyruvate-
free DMEM (Life Technologies) containing 50 g/ml penicillin and 50
g/ml streptomycin (Sigma) with 20% FBS (Life Technologies). MEFs
were received as primary cells and were immortalized through their crisis
stage by repeated 1:1 passages until cells became permissible for growth in
tissue culture flasks. Once they were immortalized, MEFs were regularly
passaged for maintenance as described above. All cells were grown at 37°C
in an atmosphere with 5% CO2 and 95% humidity. VACV-A5-EGFP
(VACV-EGFP) has been described previously (23). The viruses used in all
experiments were purified by high-speed centrifugation through a 36%
(wt/vol) sucrose cushion.
siRNA transfection. The siRNA transfection method has been described
previously (14). siRNAs (Dharmacon/Thermo Scientific) were added to a
final concentration of 25 nM, and the cells were incubated at 37°C in 5% CO2
for 48 h before further experimental steps were carried out. The sequences of
the siRNAs used in this work are as follows: for VP16, GGGCGAAGUUGG
ACUCGUAUU; for RAB1A (SMARTpool), GAACAAUCACCUCCAG
UUA, CAAUCAAGCUUCAAAUAUG, GGAAACCAGUGCUAAGAAU,
and CAGCAUGAAUCCCGAAUAU; for VPS52 (SMARTpool), CGAAAGA
GGCAGUAAGGAA, GAUCACACCCACAAUGAAA, GGCAAUGUCUCC
ACGGCAA, and CCAGAUGAUGGUUGAACAU; for VPS35 (SMART-
pool), GAACAUAUUGCUACCAGUA, GAAAGAGCAUGAGUUGUUA,
GUUGUAAACUGUAGGGAUG, and GAACAAAUUUGGUGCGCCU;
and for VPS26 (SMARTpool), GCUAGAACACCAAGGAAUU, UAAAGU
GACAAUAGUGAGA[, UGAGAUCGAUAUUGUUCUU, and CCACCUA
UCCUGAUGUUAA.
Western blotting.Cells were washed twice with ice-cold PBS and then
lysed in protein lysate buffer (50 mM Tris-Cl, pH 7.5, 100 mM NaCl, 1%
[wt/vol] NP-40) and 1:7 protease inhibitor (Complete tablets; Roche) on
ice for 30 min before storage at 70°C. After thawing, lysates were cen-
trifuged at 16,100  g for 5 min and the pellet was discarded. A bicin-
choninic acid (BCA) protein assay kit (Thermo Scientific Pierce) was used
to calculate protein concentrations according to the manufacturer’s pro-
tocol, and equal amounts of protein were loaded for Western blotting,
which was carried out as described previously (24). The primary antibod-
ies used were rabbit anti-VPS52 (catalog no. ARP57644_P050; Aviva Sys-
tem Biology), mouse anti-actin (catalog no. 3700S; Cell Signaling), and
anti-VPS35 (catalog no. Ab57632; Abcam), anti-VPS26 (catalog no.
Ab23892; Abcam). The secondary antibodies were DyLight 680 and 800
(Cell Signaling).
One-step and multistep growth curves. One-step and multistep
growth curves have been described previously (24, 25). Briefly, for one-
step growth curves, cells were infected at a multiplicity of infection (MOI)
of 5 PFU/cell for 1 h at 37°C and then washed with medium and incubated
for the times indicated below. Supernatants were collected and centri-
fuged at low speed to remove the cell debris and then incubated with
anti-L1 antibody (BEI Resources) for 1 h at 37°C in order to neutralize
IMV particles. The titers of the virus present in the supernatants and
cellular fraction were then determined on BS-C-1 cells. For the multistep
growth curves, cells were infected at a low MOI (0.05 or 0.1 PFU/cell) for
1 h at 37°C. At the times indicated below, the supernatant and cellular
fraction were combined by scraping the cells into the supernatant, and
titers were determined by plaque assay on BS-C-1 cells.
Immunofluorescence. Cells to be examined for immunofluorescence
were seeded on 20-mm by 20-mm coverslips at a density of 1.5 105 cells
for HeLa cells and 2 105 cells per well for MEFs, and the coverslips were
placed into six-well plates. The cells were fixed with 2 ml of neutral buff-
ered formalin for 30 min, washed in PBS, permeabilized in 0.2% Triton
X-100 for 5 min at room temperature, and washed 3 times in PBS. The
cells were incubated with primary antibody at room temperature (RT) for
1 h in a humidity chamber. The coverslips were washed three times in
PBS–2% FBS before addition of secondary antibody and fluorescently
labeled phalloidin (Molecular Probes) diluted in PBS–2% FBS for 1 h at
RT in a humidity chamber. After washing three times in PBS and once in
distilled water, the coverslips were mounted in ProLong Gold mounting
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medium containing DAPI (4=,6-diamidino-2-phenylindole; Molecular
Probes). The slides were examined on a Zeiss 710 confocal microscope.
The primary antibodies used were sheep anti-TGN46 (catalog no.
AHP500; AbD Serotec), mouse anti-B5 (catalog no. NR-556; BEI Re-
sources), and rat anti-F13. Secondary antibodies were sourced from Life
Technologies (Alexa Fluor 488-conjugated goat anti-rabbit immunoglob-
ulin, Alexa Fluor 568-conjugated goat anti-rabbit immunoglobulin, Alexa
Fluor 568-conjugated goat anti-mouse immunoglobulin, and Alex Fluor
594-conjugated donkey anti-sheep immunoglobulin).
Imaris image analysis. Three-dimensional (3D) image analysis was
carried out using Imaris image analysis software (Imaris, version 8.2; Bit-
plane AG, Switzerland). Two-dimensional confocal z-stacks were ac-
quired on a Zeiss 710 microscope and rendered into three dimensions.
The ImarisCell module was then used to segment the nucleus, cell, and
B5-labeled vesicles. Vesicles were exported to spots and filtered for en-
hanced green fluorescent protein (EGFP) colocalization to identify B5-
labeled structures with a core center.
Pharmacological inhibition of retrograde transport in vitro.
Retro-1, VP-184, Retro-2, and Retro-2.1 were synthesized in-house (26,
27) and resuspended in dimethyl sulfoxide (DMSO) before serial dilution
to a range of concentrations in FBS-free, antibiotic-free DMEM. Appro-
priate dilutions were added to a 6-well plate seeded with HeLa cells, and
the plates were incubated for 2 h at 37°C in 5% CO2 before infection with
VACV-EGFP for the length of time indicated below. The drugs remained
present throughout infection and postinfection incubation. VP-184 is a
Retro-1 analogue which gives increased protection against Shiga toxin
and Simkania negevensis (28), and Retro-2.1 is an N-methyldihydro-
quinazolinone derivative of Retro-2 with enhanced efficacy against Shiga
toxin (26).
Retro-2 intraperitoneal administration. Retro-2 was resuspended in
DMSO to a concentration of 66.6 mg/ml (210 mM). Groups of 6 mice
were injected intraperitoneally with 270 l of PBS supplemented with 30
l (10%, vol/vol) DMSO alone (control) or 30 l Retro-2.
Intranasal infection of mice. BALB/c mice (female; age, 6 to 8 weeks)
were inoculated with VACV-WR, which had been purified by sedimenta-
tion through a sucrose cushion. The mice were lightly anesthetized with
isoflurane before 1 104 PFU VACV-WR diluted in 20 l PBS was inoc-
ulated into the nostril. The mice were monitored daily for weight loss and
scored for clinical signs of disease (hair ruffling, hunched back, reduced
mobility). All animal experiments were carried out under a UK Home
Office license and assessed by the local Animal Ethics and Welfare Com-
mittee.
Titration of virus from mouse lungs. Lungs from each mouse were
placed in a safe-lock Eppendorf tube (Eppendorf) with one 5-mm stain-
less steel bead (Qiagen) and 1 ml DMEM supplemented with 2.5% FBS
and pen/strep antibiotics. The tubes were arranged evenly and securely in
a Qiagen TissueLyser II tissue disrupter, and the lung tissue was thor-
oughly disrupted by high-speed shaking (two pulses of 28,000 Hz for 2
min). Samples were then transferred to fresh standard Eppendorf tubes
and spun on a tabletop centrifuge for 5 min at 3,000 rpm. The superna-
tants were titrated by plaque assay on BS-C-1 cells.
RESULTS
The GARP complex is required for multistep replication of
VACV. The GARP complex is a tetramer composed of four pro-
teins (VPS51, VPS52, VPS53, and VPS54). It localizes to the TGN,
where it acts as a tethering factor, receiving transport vesicles that
are traveling back from endosomes. Knockdown of a single com-
ponent of the tetramer destabilizes the complex and results in the
rapid decay of all four components and impaired retrograde trans-
port (29, 30). Two subunits of the GARP complex (VPS54 and
VPS52) were identified to be strong proviral host factors in inde-
pendent siRNA screens of VACV replication (13, 14). In order to
investigate this further, the levels of VPS52 protein were depleted
using siRNA and the impact on VACV multistep replication was
measured. HeLa cells were mock transfected or transfected with
either a nontargeting control siRNA (targeting herpes simplex vi-
rus 1 [HSV-1] protein VP16) or siRNA targeting VPS52. A siRNA
SMARTpool containing four different siRNAs, all of which tar-
geted VPS52, was used to enhance the magnitude and specificity of
protein knockdown. After 48 h of transfection, the cells were har-
vested and the level of VPS52 in the cell lysates was compared
using Western blotting. In cells transfected with VPS52-targeting
siRNA, the level of VPS52 was consistently reduced to approxi-
mately 60% of the level in cells treated with nontargeting control
siRNA (Fig. 1A and B), confirming the efficacy of the SMART-
pool.
The impact of VPS52 reduction on the functioning of retro-
grade transport pathways was assessed by examining the location
of the endogenous TGN marker TGN46, which is known to be
transported on retrograde pathways (17). HeLa cells were mock
transfected or transfected with siRNA targeting VPS52 or nontar-
geting control siRNA and, after 48 h, fixed and labeled with anti-
body raised against TGN46 as well as with fluorescent phalloidin
to outline the cytoskeleton. In the mock-transfected and nontar-
geting siRNA-transfected cells, TGN46 displayed a classic perinu-
clear location, consistent with the location of the trans-Golgi net-
work. However, in cells transfected with siRNA targeting VPS52,
the localization of TGN46 was altered to a much more punctate,
juxtanuclear distribution (Fig. 1C), consistent with the findings
presented in previous reports (17). When multiple cells were
scored for normal or collapsed TGN46 localization, a highly sta-
tistically significant disruption of TGN46 localization, indicative
of the disruption of EGRTP function, was evident in response to
the depletion of VPS52 (Fig. 1D).
The impact of VPS52 on VACV replication and spread was
then examined using VACV-A5-EGFP, a VACV strain which has
the A5 viral core protein tagged with EGFP, thereby enabling virus
growth to be estimated by measuring fluorescence levels (14, 23).
HeLa cells were mock transfected or transfected with nontargeting
siRNA (a negative control); siRNA targeting RAB1A (a positive
control), which is required for efficient VACV replication (25); or
the VPS52 siRNA SMARTpool. In addition, the VPS52 SMART-
pool was deconvoluted to its four constituent siRNAs, and each
was tested individually. After 48 h, the cells were infected with
VACV-A5-EGFP at a low MOI of 0.1 PFU/cell, and fluorescence
was measured at 12-h intervals for a further 48 h, allowing mul-
tiple rounds of virus replication to occur (Fig. 1E). Fluores-
cence levels increased over time, as expected, and were compa-
rable in the negative-control samples (mock and VP16
transfected) but significantly reduced at 36 and 48 h postinfec-
tion (p.i.) in the wells treated with positive-control siRNA
(RAB1A), the VPS52 SMARTpool, and all four of the decon-
voluted VPS52 siRNAs.
In order to determine directly the effect of depletion of VPS52
on infectious virion production, the experiment was repeated and
VACV replication was measured using virus titration (Fig. 1F).
After 48 h there was an average of a 1-log10 reduction in the
amount of virus produced in the positive-control samples de-
pleted of RAB1A, consistent with previous findings (25). In cells
depleted of VPS52, there was a smaller but reproducible and sta-
tistically significant (P  0.05) reduction of 0.5 log10 in the
amount of virus detected compared to the amount in the negative-
control samples transfected with nontargeting siRNA. Overall,
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these results substantiate previously reported evidence from the
high-throughput siRNA screens that VPS52 is required for the
efficient multicycle growth of VACV.
Genetically induced destabilization of GARP impairs VACV
replication. Depletion of GARP using siRNA resulted in a consis-
tent and significant reduction of VACV replication in HeLa cells,
but one that was less marked than that seen in response to deple-
tion of other proviral host factors previously investigated (14). A
possible explanation for this was the limited efficacy of the VPS52
siRNA treatment. As seen in Fig. 1D, 25% of the population of
cells transfected with VPS52-targeted siRNA showed normally
distributed TGN46, suggesting that the protein knockdown was
insufficient in all cells to fully ablate EGRTP function. In order to
achieve a uniform reduction in EGRTP function and to validate
FIG1 Reduced expression of VPS52 impairs multistep growth of VACV. (A) HeLa cells were transfected with nontargeting siRNA (NT) or a SMARTpool of four
siRNAs targeting VPS52. After 48 h, cells were harvested and proteins were separated using SDS-PAGE, probed with antibody raised against VPS52 or actin, and
visualized using direct infrared fluorescence (LI-COR) in an Odyssey scanner. (B) The levels of VPS52 relative to those of actin were quantified. Data represent
the averages from three biological replicates. Error bars are SEMs. ***,P 0.001 by two-tailed Student’s t test. (C) HeLa cells were mock transfected or transfected
with nontargeting siRNA or siRNA targeting VPS52. After 48 h, cells were fixed and labeled with antibody raised against TGN46 and phalloidin. (D) The
percentage of cells with a normal punctate TGN46 distribution was calculated. ***, P 0.001 by two-tailed Student’s t test. (E) HeLa cells were transfected with
a VPS52 siRNA SMARTpool (VPS52) and the four individual deconvoluted VPS52 siRNAs (DC1 to DC4). Negative controls included mock-transfected cells and
cells transfected with nontargeting siRNA. siRNA targeting a known proviral host factor (RAB1A) was used as the positive control. After 48 h, cells were infected
with VACV-EGFP at 0.1 PFU/cell, and fluorescence levels were measured over the following 48 h. The data represent those from six technical replicates and are
representative of those from three biological replicates. Error bars represent SEMs. Results were analyzed with a one-way analysis of variance with multiple
comparisons at 48 h postinfection. ***, P 0.001. (F) HeLa cells were mock transfected or transfected with nontargeting siRNA or siRNA targeting VPS52 or
RAB1A. After 48 h, cells were infected with VACV-EGFP at 0.1 PFU/cell, and at 48 h p.i., cells and supernatant were collected and virus titers were determined.
Data were analyzed with a one-way analysis of variance with multiple comparisons. ***, P 0.001; **, P 0.01; *, P 0.05.
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the siRNA knockdown findings using an alternative method, we
used a mouse genetic mutant with a hypomorphic mutation in the
VPS54 subunit of GARP (30). In this mouse, a single missense
mutation converting codon 967 of the vps54 gene from leucine to
glutamine results in an unstable VPS54 protein with a shortened
half-life (29). This results in less overall GARP and a partial loss of
function, as seen in slower transport and mislocalization of the
retrograde-dependent cholera toxin B subunit (31). Wild-type
(WT) and mutant (MU) primary mouse embryonic fibroblasts
(MEFs) were isolated and immortalized through serial passage. In
the following experiments, two independently derived WT cell
lines and two MU cell lines were included to reduce the likelihood
that off-target mutations produced during immortalization were
responsible for the phenotype seen.
To confirm that the hypomorphic mutation destabilizes the
GARP complex, cell lysates of WT and MU immortalized MEFs
were collected and the levels of VPS52 were compared using West-
ern blotting. As shown in Fig. 2A and B, the levels of VPS52 pro-
tein were significantly reduced in the mutant cells by an average of
52%. A VACV multistep growth curve was then carried out on the
two WT cell lines and the two MU cell lines, and the amount of
virus present was determined by titration (Fig. 2C). A clear differ-
ence in virus titer between the WT and MU cell lines was apparent
from 12 h p.i., with an approximately 1-log10 reduction in the
amount of virus being present in both MU cell lines at 12, 24, and
36 h p.i., and the amount narrowed to 0.5 log10 at 48 h p.i. as virus
production plateaued. This result confirms by an independent
method and in a second cell type that GARP is required for opti-
mal multistep VACV replication.
GARP is required for production of IEVs and CEVs but not
IMVs. In order to examine the impact of GARP depletion on the
different virion forms produced during VACV replication, we car-
ried out a one-step growth curve on WT and MU MEFs, infecting
the cells at a high MOI (5 PFU/cell) and measuring virus produc-
tion over the following 24 h. The titers of virus present in the cells
and the supernatant were determined separately. Neutralizing an-
tibody to IMVs was added to the supernatant fraction prior to
titration to ensure that only the titers of EEVs that had been re-
leased from the cell were determined. No significant difference in
the amount of virus produced in the cellular fraction (which con-
sists almost entirely of IMVs) was detected at any time point (Fig.
2D), suggesting that initial stages of virus production were unaf-
fected by GARP depletion. However, a reduction in virus titer in
the supernatant fraction of up to 1 log10 in the MU cells compared
to the titers in the WT cells was detected at 8, 12, and 24 h p.i. (Fig.
2E), indicating that fewer EEVs were produced from cells lacking
normal levels of GARP.
To identify the point at which EEV production was impacted
by reduced levels of GARP, we assessed and compared the number
of IEVs and CEVs present in the WT and MU MEFs using immu-
nolabeling and confocal fluorescence microscopy. MEFs were in-
fected with VACV-A5-EGFP at a high MOI of 5 PFU/cell and,
FIG 2 Mutation of the GARP complex reduces VACV replication in a multistep growth curve. (A) Protein lysates were collected from two independently
immortalized lines of wild-type MEFs (WT1 and WT2) and mutated MEFs (MU1 and MU2), separated using SDS-PAGE, probed with antibody raised against
VPS52 or actin, and visualized using direct infrared fluorescence (LI-COR) in an Odyssey scanner. Numbers on the left are molecular sizes (in kilodaltons). (B)
The levels of VPS52 relative to those of actin were quantified. Data represent the averages from three biological replicates. Error bars are SEMs. **, P  0.01,
one-way analysis of variance with multiple comparisons. (C) Multistep growth curve. WT or MU MEFs were infected with VACV-WR at 0.01 PFU/cell. Cells
were harvested at the indicated times p.i., and total virus levels were determined by plaque assay on BS-C-1 cells. The graph shows the mean titer from three
biological replicates. Error bars indicate SEMs. *, P 0.05, one-way analysis of variance with multiple comparisons at 48 h p.i. (D and E) One-step growth curve.
WT or MU MEFs were infected with VACV-WR at 5 PFU/cell. At the indicated times p.i., cells (D) and supernatant (E) were collected and virus titers were
determined by plaque assay on BS-C-1 cells. The graphs show the mean titers from three biological replicates. Error bars indicate SEMs. *, P 0.05, one-way
analysis of variance with multiple comparisons.
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after 8 h, fixed, permeabilized, and labeled with antibody targeted
to the IEV/CEV membrane protein B5 (32). Single optical slices
taken through infected WT cells showed that the EGFP-tagged A5
protein was distributed in the expected pattern of large perinu-
clear viral assembly factories as well as in much smaller dispersed
cytoplasmic puncta representing individual virus cores (Fig. 3A,
top). Many, but not all, of these cores also stained positive for B5,
thereby identifying them as IEVs/CEVs. However, this pattern
altered in GARP mutant cells, as while there were still abundant
peripherally dispersed viral cores (consistent with the unaltered
titers of cell-associated virus), there were noticeably fewer puncta
of B5 staining (Fig. 3A, bottom). Furthermore, high-magnifica-
tion analysis of viral core and B5 localization showed that while
most B5 puncta colocalized with the VACV-A5-EGFP fluores-
cence in WT cells (indicating that the foci were indeed IEV/CEVs),
the MU cells contained many more B5 foci that lacked an associ-
ated core (Fig. 3B). Twenty-five WT and 24 MU cells from three
independent experiments were analyzed by taking z-stacked im-
ages throughout the depth of the cells, reconstructing them as a 3D
image, and analyzing the data using Imaris image analysis soft-
ware to quantify the number of B5-labeled puncta. WT cells con-
tained, on average, over 450 puncta per cell, but this was more
than 2-fold lower in the MU cells (Fig. 4A). Analysis of the number
of B5 puncta that coincided with EGFP fluorescence also con-
firmed a statistically significant drop in the proportion associated
with cores, from over 90% in WT cells to about 60% in MU cells
(Fig. 4B). However, when cells were costained for B5 and another
IEV/CEV membrane protein, F13, there was no decrease in the
level of colocalization in the MU cells, with a high proportion
(over 90%) of vesicles being double positive for both IEV/CEV
membrane proteins in WT and MU cells (Fig. 4C).
Further differences between B5-labeled structures in the cyto-
plasm of WT and MU MEFs were also evident, in that B5-labeled
puncta in the MU cells showed more variation in size and had a
small but statistically significant increase in their average diameter
compared with IEVs/CEVs in the WT cells, from 0.96 m to 1.08
m. Frequency analysis of the data showed that this reflected an
increase in the population of puncta with diameters of1.6m in
the MU cells (Fig. 4D). The two populations of B5 puncta in the
MU cells were compared. The abnormal B5-labeled structures
lacking an associated core were found to be significantly larger
(125%) than the puncta associated with a core (IEVs/CEVs) (Fig.
4E). These results reveal that IMV wrapping is disrupted when the
GARP complex is dysfunctional, resulting in accumulation in the
cytoplasm of aberrant large B5-labeled puncta lacking an internal
core.
VACVreplication is independentof the retromer cargo-sort-
ing protein complex. In order to define the retrograde transport
pathway components involved in VACV replication, we investi-
gated the role of the retromer complex. Retromer is a well-char-
acterized key component of endosome-to-Golgi retrograde path-
ways. It is located in the endosomal membrane and acts as a cargo
FIG 3 Mutation of the GARP complex impairs production of IEVs. (A) WT and MU MEFs were infected with VACV-A5-EGFP (green) at 5 PFU/cell for 8 h and
then fixed and labeled with anti-B5 antibody (red), phalloidin (orange), and DAPI (blue). Images are representative confocal sections acquired with a Zeiss LSM
710 confocal microscope. (B) 3D reconstruction of z-stack confocal series of WT and MU MEFs infected with VACV-EGFP. (Top) DAPI (blue), VACV cores
(green), B5 (red), and actin (phalloidin, gray); (bottom) the same images from the top panels with the red (B5) channel removed.
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sorter, binding to cargo in the lumen that is destined for retro-
grade trafficking and facilitating the formation and budding off of
retrograde transport vesicles (33). We separately targeted two sub-
units of retromer (VPS35 and VPS26) using siRNA transfected
into HeLa cells. Western blotting indicated successful knockdown
of protein expression to levels less than 50% of those detected in
cells transfected with nontargeting siRNA (Fig. 5A to D). To con-
firm that retrograde transport was disrupted in these cells, the
location of TGN46 was examined. Cells with reduced levels of
VPS35 or VPS26 revealed an abnormal localization of TGN46,
confirming functional disruption (Fig. 5E). The efficacy of multi-
step VACV growth in cells with a knockdown in expression of
either the VPS26 or the VPS35 subunit of the retromer complex
was then assessed by infecting the siRNA-transfected cells with
VACV-A5-EGFP at a low MOI of 0.1 PFU/cell and measuring the
fluorescence every 12 h as a marker of virus replication (Fig. 5G).
The positive-control siRNA which targets RAB1A, a known pro-
viral host factor, reduced the fluorescence levels by over 25% at 48
h p.i.; however, a reduction of either retromer subunit had no
significant effect on VACV replication compared to that in mock-
transfected cells or cells transfected with the control nontargeting
siRNA. No significant difference in cell death was detected in the
different treatment groups after 48 h of virus infection, proving
that the siRNA treatments were not toxic (Fig. 5F). This result
suggests that VACV uses a nonclassical, retromer-independent
retrograde trafficking pathway.
VACV is susceptible to pharmacological inhibition of retro-
grade transport pathways. Toxins such as ricin, Shiga toxin, and
cholera toxin use EGRTP to escape the endosomal compartment
and travel through the cytosol of the cell (16). A high-throughput
screen of a small-molecule library in a ricin cytotoxicity assay
identified potent pharmacological inhibitors of EGRTP, including
Retro-1 and Retro-2, two compounds with a heterocyclic struc-
ture incorporating a central benzodiazepine or imine moiety (34).
The mechanisms of function of Retro-1 and Retro-2 are un-
known; however, they both cause a rapid redistribution of the
SNARE protein syntaxin 5 (22, 34). The effect of both drugs is
highly specific to retrograde endosome-to-TGN pathways; nei-
ther drug interferes with anterograde transport along the biosyn-
thetic/secretory pathway from the endoplasmic reticulum via the
Golgi apparatus and TGN to the plasma membrane or with endo-
cytosis, recycling from the early endosome back to the plasma
membrane or trafficking to late endosomes and the lysosome (31,
34). This specificity of action makes Retro-1 and -2 powerful tools
when investigating retrograde transport.
The effect of Retro-1 and Retro-2 on VACV multistep replica-
tion was investigated. In addition, two related drugs, VP-184 and
Retro-2.1, were also tested. VP-184 is closely related to Retro-1
(28), while Retro-2.1 is a novel, highly potent derivative of Retro-2
(26). HeLa cells were pretreated for 1 h with various concentra-
tions of drug and then infected at a low MOI (0.05 PFU/cell) with
VACV-A5-EGFP, and fluorescence was measured over the follow-
ing 48 h. At 48 h p.i., cell viability was measured using CellTiter-
Blue (Promega) and compared to the viability of cells infected and
treated with medium alone. Increased levels of cell death were
detected only at the highest concentration (100 M) of Retro-1,
VP-184, and Retro-2.1 tested (Fig. 6A). No cell death was present
even at a 100 M Retro-2 concentration, indicating a very low
FIG 4 Mutation of the GARP complex disrupts the wrapping of IMVs, resulting in aberrant B5 accumulations. Imaris image analysis software (Bitplane) was
used to quantitate the number of B5-labeled puncta in each cell (A), the percentage of B5-labeled puncta in a cell which colocalized with an EGFP-labeled core
(B), the percentage of B5 puncta which colocalized with F13 (C), and the diameter of B5-labeled puncta in WT and MU MEFs (D). Data represent the averages
and SEMs from an analysis of 49 cells (24 WT and 25 MU cells) from three independent experiments. ***, P  0.001 by two-tailed Student’s t test. (E) The
diameter of B5-labeled puncta in MU MEFs was compared. The diameter of normal B5-labeled puncta which were associated with an EGFP-labeled core and the
diameter of abnormal B5-labeled puncta with no associated core were compared. Data represents the averages and SEMs from an analysis of 25 MU cells from
three independent experiments. ***, P 0.001 by two-tailed Student’s t test.
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FIG 5 VACV morphogenesis is independent of the retromer complex. HeLa cells were mock transfected or transfected with nontargeting siRNA (NT) or siRNA
targeting VPS35 (A) or VPS26 (B). After 48 h, cells were harvested and proteins were separated using SDS-PAGE, probed with antibody raised against VPS35 or
actin, and visualized using direct infrared fluorescence (LI-COR) in an Odyssey scanner. The levels of VPS35 (C) and VPS26 (D) relative to those of actin were
quantified. (E) HeLa cells were mock transfected or transfected with nontargeting siRNA or siRNA targeting VPS26 or VPS35. After 48 h, cells were fixed and
labeled with antibody raised against TGN46 and phalloidin. The percentage of cells with a normal punctate TGN46 distribution was analyzed. (F and G) HeLa
cells were mock transfected or transfected with nontargeting siRNA or siRNA targeting VPS35, VPS26, or RAB1A (positive control). (G) After 48 h, cells were
infected with VACV-EGFP at 0.1 PFU/cell and fluorescence was measured at the indicated times. (F) At 48 h p.i., cell death was measured using CellTiter-Blue
and is presented as arbitrary fluorescence units. The data represent those from six technical replicates, and error bars represent SEMs. Results were analyzed by
Student’s t test. ***, P 0.001. kd, knockdown.
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FIG 6 Inhibition of retrograde transport with small-molecule inhibitors reduces IEV production. (A) HeLa cells were treated with various concentrations of
drug, as indicated, and infected with VACV-EGFP at 0.1 PFU/cell. After 48 h, cell death was measured using CellTiter-Blue. Cell death is expressed as a percentage
of the survival of infected cells treated with medium alone. Data are averages and SEMs from six technical replicates. (B to E) HeLa cells were treated with various
concentrations of the indicated drug and infected with VACV-EGFP at 0.1 PFU/cell. Fluorescence was measured at the indicated time points. Data are average
and SEMs from six technical replicates and were analyzed using a one-way analysis of variance with multiple comparisons of the data at 48 h postinfection. ***,
P 0.001. (G and H) One-step growth curve. HeLa cells were treated with the compounds indicated and infected with VACV-WR at 5 PFU/cell. At 0 and 24 h
p.i., cells (F) and supernatants (G) were collected and virus titers were determined by plaque assay on BS-C-1 cells. ***, P 0.001, one-way analysis of variance
with multiple comparisons of the data at 48 h postinfection.
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toxic impact of the drug. EGFP fluorescence measurement re-
vealed a strong inhibitory effect of Retro-1, VP-184, Retro-2, and
Retro-2.1 on VACV growth (Fig. 6B to E) compared to the growth
of the controls treated with medium or DMSO. This suggests that
endosome-to-Golgi apparatus trafficking is required for VACV
multistep replication.
The concentrations of Retro-1 (1M and 10M) and Retro-2
(10 M and 100 M) that showed efficacy against VACV replica-
tion are comparable to the concentration (25 M) used to block
the activity of ricin and Shiga toxin (34). When comparing the
effective concentrations of Retro-2 and Retro-2.1, we found that
the more potent derivative drug, Retro-2.1, displayed a 100-fold
increase in efficacy against VACV, with over 90% inhibition of
virus replication being found at a concentration of just 100 nM.
This finding is similar to that of previously reported work which
found Retro-2.1 to be 100-fold more potent at preventing AAV
transduction (22) and 500- to 1,000-fold more potent at blocking
Shiga toxin and ricin toxicity (27).
To determine the stage of the VACV life cycle that is targeted by
the four retrograde transport inhibitors, a one-step growth curve
was carried out in the presence of drug, DMSO, or medium alone,
and the cell-associated virus titer was determined separately from
the titer of virus present in the supernatant after 24 h of infection.
There was no detectable difference in the titer of cell-associated
virus, with a greater than 2-log10 increase in the amount of virus
present in all samples being found after 24 h. In contrast, the
amount of EEV in the supernatant increased by over 1.5 log10
in the control samples treated with medium alone or carrier
(DMSO) but less than 1 log10 in the samples treated with any of the
four drugs (Fig. 6F and G). These results are strikingly similar to
those obtained from one-step growth curves of MEFs expressing a
GARP mutant (Fig. 2D and E) and provide compelling evidence
that VACV uses EGRTP to facilitate virion morphogenesis.
Retro-2 treatment alleviates systemic disease in mice in-
fected with VACV. Inhibition of EGRTP in vitro strongly inhib-
ited the production of EEVs. In vivo EEVs are the virion form
responsible for the systemic spread of VACV around the body (5,
7). We therefore investigated whether pharmacological inhibition
of EGRTP influenced disease in mice experimentally infected in-
tranasally with VACV. Mice were injected intraperitoneally with
100 mg of Retro-2 per kg of body weight on two occasions. One
group received the drug 24 h before and 24 h after infection with
1 104 PFU VACV, while a second group received the drug 24 h
and 48 h after infection with VACV. Control groups received no
drug and no virus, drug alone, or virus inoculation plus intraper-
itoneal (i.p.) injection of vehicle alone (DMSO). Mice given i.p.
drug but no virus consistently gained weight across the experi-
ment and were indistinguishable from the negative-control group
of mice given no drug or virus (Fig. 7A; compare groups 1, 5, and
6). This confirms previous reports of the excellent safety profile of
Retro-2 after i.p. injection in mice (34–36). As expected, mice
infected with VACV and treated with DMSO lost weight rapidly
between day 4 and day 7 of the experiment and exhibited ruffled
fur, a hunched posture, and reduced activity. Three out of the 6
mice in this group were euthanized due to the severity of clinical
signs. Mice infected with VACV and treated with Retro-2 at 24 and
FIG 7 Retro-2 treatment prior to VACV infection ameliorates weight loss and clinical signs of disease in mice. BALB/c female mice were randomly assigned to
6 groups of 6 mice each. Mice in group 1 were untreated and uninfected controls. Mice in group 2 were infected with 1  104 PFU of purified VACV-WR
intranasally (i.n.) on day 0 and sham treated with a 300-l i.p. injection of the 10% (vol/vol) DMSO in PBS vehicle (Veh.) on days1 and2 p.i. Mice in group
3 were treated with 100 mg/kg Retro-2 i.p. on days1 and1 and inoculated with 1 104 PFU of purified VACV-WR i.n. on day 0. Mice in group 4 were infected
i.n. with 1 104 PFU VACV-WR and treated with 100 mg/kg Retro-2 i.p. on days1 and2 p.i. Mice in group 5 were treated with 100 mg/kg Retro-2 i.p. on
days1 and1 p.i. Mice in group 6 were treated with 100 mg/kg Retro-2 i.p. on days1 and2 p.i. Mice in both groups 5 and 6 were left uninfected. All mice
were monitored daily for weight change (A) and clinical signs of disease (B). (C) At the termination of the experiment (day 7), the viral loads in the lungs of mice
in groups 2, 3, and 4 were determined by plaque assay. Statistical analysis was carried out using Student’s t test to compare groups 2 and 3. *, P 0.05; **, P
0.01; ***, P 0.001. Each animal that reached the humane endpoint and then euthanized is indicated (†).
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48 h postinfection lost weight just as rapidly as the untreated in-
fected mice, and one mouse was euthanized. However, mice
treated with Retro-2 24 h prior to and 24 h after VACV infection
lost less weight (P  0.05) and exhibited significantly less severe
clinical signs of disease (P 0.01) (Fig. 7A and B; compare group
3 with groups 2 and 4). None of the mice in this group reached the
humane endpoint requiring euthanasia, revealing a protective ef-
fect of Retro-2 on VACV-induced disease in mice. The amount of
virus in the lungs of each mouse in groups 2, 3, and 4 was deter-
mined (Fig. 7C). The average number of PFU of VACV in the
lungs of mice in group 3 was lower than that in the lungs of mice in
groups 2 and 4; however, this reduction did not reach the level of
statistical significance (group 2 versus group 3,P 0.07, Student’s
t test).
DISCUSSION
This work outlines the reliance of VACV on cellular endosome-
to-Golgi retrograde transport pathways in order to produce the
wrapped IEV form. Retrograde pathways were inhibited by three
different mechanisms (siRNA knockdown, a genetic hypomor-
phic mutation, and pharmacological inhibition), all of which re-
sulted in a significant reduction in VACV multistep replication.
Closer analysis revealed that the levels of IMV were unaffected by
a reduction of the level of expression of the GARP complex; how-
ever, there was a drop in the number of IEVs/CEVs accompanied
by aberrant accumulations of B5, indicating that the wrapping of
IMVs had been disrupted. Wrapping of IMVs in an additional two
layers of membrane is a poorly understood but crucial process in
the life cycle of VACV and other poxviruses (2). The site of wrap-
ping is debated, with evidence suggesting either the TGN (12) or
endosome (11). The viral proteins A27, F13, and B5 are necessary
for wrapping to occur, but the exact function of each of these
proteins in the process is unclear (37–39). The identification of
retrograde pathways and, specifically, the GARP complex as a
crucial component of this process marks a decisive step for-
ward in our understanding of this unique stage of poxvirus
morphogenesis.
The GARP complex was targeted in our studies on the basis of
results from two siRNA screens. A screen from our laboratory
identified the VPS52 subunit to be a strong proviral host factor
(14), and a second independent screen identified the VPS54 sub-
unit (13). GARP is a member of the CATCHR (complexes associ-
ated with tethering containing helical rods) family of multisub-
unit tethering complexes, which are large proteins or protein
complexes that establish long-range interactions between trans-
port vesicles and their target compartment. GARP is localized to
the TGN, where it facilitates tethering and, ultimately, the fusion
of transport vesicles traveling in a retrograde direction from en-
dosomes to the TGN (40). Cargoes which require GARP for trans-
port to the TGN include receptors for lysosomal hydrolase
precursors, such as the mannose 6-phosphate receptors, the TGN-
resident protein TGN46 (17), and sphingolipids (18). Our work
supports a model whereby the GARP complex tethers transport
vesicles containing viral membrane proteins as they are recycled
back from the plasma membrane to the TGN via retrograde trans-
port pathways for reuse. VACV proteins embedded in the outer
membrane of IEVs, including B5 and F13, remain on the surface
of the cell after the IEV fuses with the plasma membrane during
virion exit from the cell (1), and green fluorescent protein-tagged
overexpressed B5 or F13 chimeras have been shown to relocate
from the cell surface to a juxtanuclear location (8–10), suggesting
retrograde transport of these crucial membrane proteins. In this
model, the abnormal B5 puncta that lack an internal core that
were identified in the MEFs with a mutated GARP complex would
represent returning transport intermediates which were unable to
dock with the site of IMV wrapping and IEV production. This
model would support the hypothesis that the wrapping mem-
branes originate from the TGN. However, we cannot rule out an
alternative model whereby the GARP complex is needed for the
recycling and correct localization of an as-yet-unidentified host
protein(s) which is required for the wrapping process. In this
model, the abnormal B5 accumulations would represent IEV
membranes which failed to be successfully wrapped around the
IMV, somewhat analogous to HSV-1 L particles (41).
In order to characterize the abnormal B5 accumulations, we
compared the location of B5 and another IEV/CEV protein, F13,
in WT and MU MEFs. F13 colocalized with B5 in both cell types,
suggesting that the abnormal B5 puncta in the MU MEFs are likely
related to IEV wrapping membranes rather than accumulations of
individual mislocalized viral proteins.
We have uncovered evidence that VACV uses a nonclassical
route of retrograde transport that is independent of the protein
complex retromer. Previous work characterized two main retro-
grade pathways, with the first one being from early endosomes to
the TGN (sometimes via recycling endosomes) and the second
once being from late endosomes to the TGN. Each pathway in-
volves a specific set of vSNARES, tSNARES, tethers, and GTPases;
however, both rely on retromer for initial sorting of the endo-
somal cargo (16, 42). Retromer therefore plays a key role in both
these pathways and is required for retrograde transport of many
endogenous proteins as well as the correct localization of the HIV
Env protein (20), the entry of HPV16 (21), and the transport of
Shiga toxin (43, 44). Retromer is not, however, required for the
retrograde pathways involved in AAV transduction (22) or VACV
IEV formation (this work). Our results therefore confirm the ex-
istence of a retromer-independent retrograde transport pathway
distinct from the two classical pathways previously described and
highlights the complexity of cellular retrograde pathways. This
complexity makes retrograde transport an attractive therapeutic
option, since the precise inhibition of one component of a partic-
ular pathway can result in a very specific impact on a process, such
as virion wrapping, but leave other retrograde pathways func-
tional and therefore minimize indirect effects on the cell.
Our work shows that GARP is required for at least one of the
retrograde transport pathways used by VACV but does not rule
out the possibility that VACV uses multiple retrograde transport
pathways, some of which are independent of GARP.
The highly effective inhibition of VACV multistep replication
and EEV production by the retrograde transport inhibitors
Retro-1, Retro-2, and related compounds highlighted the impor-
tance of retrograde transport to poxviruses. These drugs have been
shown to inhibit processes dependent on retrograde transport, such
as the activity of ricin, Shiga toxin, and Shiga-like toxins 1 and 2 (26,
34), and the entry of AAV (22). The wrapping process of VACV is
targeted by the two well-characterized antiorthopoxvirus drugs
IMCBH [N(1)-isonicotinoyl-N(2)-3-methyl-4-chlorobenzoylhy-
drazine] and ST-246 {4-trifluoromethyl-N-[3,3a,4,4a,5,5a,6,6a-
octahydro-1,3-di oxo-4,6-ethenocycloprop [f]isoindol-2(1H)-
yl]-benzamide}. IMCBH is a selective inhibitor of VACV
multiplication (45). It targets the viral protein F13, which is essen-
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tial for wrapping but has no activity in vivo and is therefore not a
candidate for therapeutic use (46). The more recently character-
ized drug, ST-246, also targets F13 (47, 48). Retro-1 and -2 target
the same process (wrapping) as these two drugs in vitro and show
the same virus replication profiles as ST-246-treated cells, namely,
a 5- to 10-fold reduction in EEV production in a one-step growth
curve, which equates to an almost complete reduction in multi-
step growth. However, Retro-1 and -2 exert their effect via an as
yet unknown host protein rather than a viral protein and are
therefore less susceptible to viral escape via mutations in the F13
gene, as seen in VACV strains which develop resistance to IMCBH
and ST-246 (46, 48).
Retro-1 and Retro-2 have been shown to have in vivo efficacy
against ricin (34), Shiga toxin produced by enterohemorrhagic
Escherichia coli O104:H4 (36), and Leishmania (35) in mice. Since
the drugs showed strong inhibition of VACV replication in vitro,
we tested the efficacy of Retro-2 in vivo using an intranasal murine
model of poxvirus disease. We compared two treatment regimes
of 100 mg/kg given twice, either once before and once after infec-
tion (days1 and1) or twice after infection (days1 and2).
Mice treated with Retro-2 prior to infection lost less weight and
displayed less severe disease, and all mice survived the challenge.
Pretreatment with Retro-2 therefore provided protection against
poxviral disease, indicating that this family of small molecules
may be developed as novel antipoxviral drugs for diseases such as
cowpox and monkeypox and to supplement vaccination in re-
sponse to a poxviral bioterrorism event.
Note. While the manuscript for the present study was under
review, a study with broadly similar findings was published which
described the reliance of VACV on cellular retrograde pathways
for the production of IEVs (49).
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